XNASLIPO
Market cap3mUSD
Dec 24, Last price
3.16USD
1D
2.00%
1Q
601.11%
IPO
-20.75%
Name
Lipella Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
8.50
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
450k
+144.15%
Net income
-5m
L+77.92%
CFO
-3m
L+72.03%
Profile
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 450 144.15% | 184 -28.99% | 259 -73.03% | ||
Cost of revenue | 8,234 | 5,322 | 3,632 | ||
Unusual Expense (Income) | |||||
NOPBT | (7,785) | (5,137) | (3,373) | ||
NOPBT Margin | |||||
Operating Taxes | (2) | 7 | |||
Tax Rate | |||||
NOPAT | (7,785) | (5,136) | (3,379) | ||
Net income | (4,619) 77.92% | (2,596) 38.66% | (1,872) 2,717.46% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 1,612 | 4,964 | 2,097 | ||
BB yield | -26.32% | -27.61% | |||
| Debt | |||||
Debt current | 89 | 333 | 65 | ||
Long-term debt | 184 | 251 | 426 | ||
Deferred revenue | |||||
Other long-term liabilities | 30 | ||||
Net debt | (3,021) | (4,538) | (1,223) | ||
| Cash flow | |||||
Cash from operating activities | (3,150) | (1,831) | (989) | ||
CAPEX | (14) | ||||
Cash from investing activities | (14) | 301 | (301) | ||
Cash from financing activities | 1,337 | 5,239 | 2,097 | ||
FCF | (7,782) | (5,082) | (3,313) | ||
| Balance | |||||
Cash | 3,294 | 5,122 | 1,714 | ||
Long term investments | |||||
Excess cash | 3,271 | 5,113 | 1,701 | ||
Stockholders' equity | (10,323) | (5,704) | (6,213) | ||
Invested Capital | 13,604 | 10,809 | 7,950 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 6,003 | 5,744 | 5,744 | ||
Price | 1.02 -67.41% | 3.13 | |||
Market cap | 6,123 -65.94% | 17,979 | |||
EV | 3,103 | 13,441 | |||
EBITDA | (7,783) | (5,137) | (3,373) | ||
EV/EBITDA | |||||
Interest | 11 | 10 | 7 | ||
Interest/NOPBT | |||||